DK1047449T3 - Immunologiske præparater og anvendelse deraf til forbigående ændring af myelin i centralnervesystemet hos pattedyr for at fremme neuronal regenerering - Google Patents

Immunologiske præparater og anvendelse deraf til forbigående ændring af myelin i centralnervesystemet hos pattedyr for at fremme neuronal regenerering

Info

Publication number
DK1047449T3
DK1047449T3 DK98949847T DK98949847T DK1047449T3 DK 1047449 T3 DK1047449 T3 DK 1047449T3 DK 98949847 T DK98949847 T DK 98949847T DK 98949847 T DK98949847 T DK 98949847T DK 1047449 T3 DK1047449 T3 DK 1047449T3
Authority
DK
Denmark
Prior art keywords
nervous system
central nervous
neuronal regeneration
mammalian central
promote neuronal
Prior art date
Application number
DK98949847T
Other languages
Danish (da)
English (en)
Inventor
John D Cord Depts Zool Steeves
Jason K Cord Depts Zoolog Dyer
Hans S Mrc Cambridge Keirstead
Original Assignee
Univ British Columbia
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from CA 2219683 external-priority patent/CA2219683A1/fr
Application filed by Univ British Columbia filed Critical Univ British Columbia
Application granted granted Critical
Publication of DK1047449T3 publication Critical patent/DK1047449T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Endocrinology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
DK98949847T 1997-10-28 1998-10-28 Immunologiske præparater og anvendelse deraf til forbigående ændring af myelin i centralnervesystemet hos pattedyr for at fremme neuronal regenerering DK1047449T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CA 2219683 CA2219683A1 (fr) 1997-10-28 1997-10-28 Composition immunologique et methodes d'utilisation pour perturber transitoirement la myelin au systeme nerveux central de mammiferes pour promouvoir la regeneration des neuronnes
CA2251410 1998-10-16
PCT/CA1998/000997 WO1999021581A1 (fr) 1997-10-28 1998-10-28 Compositions et procedes immunologiques utilises pour modifier provisoirement la myeline du systeme nerveux central des mammiferes afin de stimuler la regeneration neuronale

Publications (1)

Publication Number Publication Date
DK1047449T3 true DK1047449T3 (da) 2004-01-26

Family

ID=25679779

Family Applications (1)

Application Number Title Priority Date Filing Date
DK98949847T DK1047449T3 (da) 1997-10-28 1998-10-28 Immunologiske præparater og anvendelse deraf til forbigående ændring af myelin i centralnervesystemet hos pattedyr for at fremme neuronal regenerering

Country Status (11)

Country Link
US (2) US6969516B1 (fr)
EP (1) EP1047449B1 (fr)
JP (1) JP2001521008A (fr)
AT (1) ATE249241T1 (fr)
AU (1) AU748143B2 (fr)
DE (1) DE69818106T2 (fr)
DK (1) DK1047449T3 (fr)
ES (1) ES2210829T3 (fr)
IL (2) IL135799A0 (fr)
PT (1) PT1047449E (fr)
WO (1) WO1999021581A1 (fr)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU4095900A (en) * 1999-04-28 2000-11-10 University Of British Columbia, The Composition for neuronal regeneration comprising myelin-specific antibodies and complement proteins
GB0103174D0 (en) * 2001-02-08 2001-03-28 Smithkline Beecham Plc Novel method of treatment
TWI323265B (en) * 2002-08-06 2010-04-11 Glaxo Group Ltd Antibodies
GB0306309D0 (en) 2003-03-19 2003-04-23 Glaxo Group Ltd Method of treatment
ES2557056T3 (es) 2006-10-10 2016-01-21 Regenesance B.V. Inhibición del complemento para una mejor regeneración de los nervios
LT2649086T (lt) * 2010-12-09 2017-11-10 The Trustees Of The University Of Pennsylvania Chimeriniu antigenų receptoriumi modifikuotų ląstelių naudojimas vėžio gydymui
TWI654206B (zh) 2013-03-16 2019-03-21 諾華公司 使用人類化抗－ｃｄ１９嵌合抗原受體治療癌症
US10058471B2 (en) * 2014-02-21 2018-08-28 William M. Vaughan System and method of using hyperbaric oxygen therapy for treating concussive symptoms and musculoskeletal injuries and for pre-treatment to prevent damage from injuries
KR20240042250A (ko) 2014-04-07 2024-04-01 노파르티스 아게 항-cd19 키메라 항원 수용체를 사용한 암의 치료
KR20170134642A (ko) 2015-04-08 2017-12-06 노파르티스 아게 Cd20 요법, cd22 요법, 및 cd19 키메라 항원 수용체 (car) - 발현 세포와의 조합 요법
WO2018067992A1 (fr) 2016-10-07 2018-04-12 Novartis Ag Récepteurs antigéniques chimériques pour le traitement du cancer

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991002003A1 (fr) * 1989-08-04 1991-02-21 Board Of Regents, The University Of Texas System Procedes et compositions; preparation purifiee de facteur regulateur de l'ascendant neural
US6020140A (en) * 1991-08-09 2000-02-01 Washington University Autoantibodies and their targets in the diagnosis of peripheral neuropathies
ATE187889T1 (de) * 1992-06-12 2000-01-15 Cephalon Inc Vorbeugung und behandlung der peripheren neuropathie
US5714385A (en) * 1995-05-10 1998-02-03 Genentech, Inc. Media for culturing schwann cells
US6228598B1 (en) * 1998-10-02 2001-05-08 Washington University Antibodies to heparan sulfate glycosaminoglycans in the diagnosis of polyneuropathies

Also Published As

Publication number Publication date
AU748143B2 (en) 2002-05-30
US6548061B1 (en) 2003-04-15
US6969516B1 (en) 2005-11-29
JP2001521008A (ja) 2001-11-06
DE69818106T2 (de) 2004-06-17
WO1999021581A1 (fr) 1999-05-06
IL135799A (en) 2011-01-31
IL135799A0 (en) 2001-05-20
ATE249241T1 (de) 2003-09-15
PT1047449E (pt) 2004-04-30
EP1047449A1 (fr) 2000-11-02
EP1047449B1 (fr) 2003-09-10
DE69818106D1 (de) 2003-10-16
ES2210829T3 (es) 2004-07-01
AU9617998A (en) 1999-05-17

Similar Documents

Publication Publication Date Title
ATE159429T1 (de) Methode zum überbringen von agenzien an zielzellen
Coulter et al. Simplified preparation of rabbit Fab fragments
DK1047449T3 (da) Immunologiske præparater og anvendelse deraf til forbigående ændring af myelin i centralnervesystemet hos pattedyr for at fremme neuronal regenerering
DE69309472T2 (de) Fusionsproteine von monomeren und dimeren von antikörperfragmenten
CY1107821T1 (el) Πολυπεπτιδιο παραγοντα viii με ενεργοτητα παραγοντα viii:c
AR001811A1 (es) Anticuerpos anti-icam-1 modificados y su uso en eltratamiento de inflamaciones
ATE248605T1 (de) Für e-selectin und p-selectin spezifische kreuzreaktive monoklonale antikörper
DE68918867T2 (de) Mutanten des hiv-1 Hüllproteins mit fehlenden hypervariabelen domänen.
ES2181674T3 (es) Dominios de union en las proteinas notch y delta.
DE69014474D1 (de) Antikörper gegen TNF-Bindungsprotein I und deren F(ab)-Fragmente.
PT743856E (pt) Heteropolimeros a base de antigenes e metodo para o tratamento de doencas auto-imunes utilizando esses heteropolimeros
DE68925593D1 (de) Antikörper-Heterokonjugate zur Regulation der Lymphozytenaktivität
ATE404583T1 (de) Funktionelle antagonisten von hedgehog-aktivität
ATE134880T1 (de) Bindung von immunkomplexen durch modifizierte formen von c-reaktiven proteinen
ATE142789T1 (de) Träger zur bindung von antiphospholipid- antikörpern, diese antikörper verwendender immunotest und kit dafür
DE69021953T2 (de) Enzymimmuntest für Antigene und dafür verwendbare feste Phase.
ATE234111T1 (de) Therapeutische verwendungen von bpi-protein produkten bei menschen mit durch trauma verursachter blutung
ATE410514T1 (de) Calciumbindende rekombinante antikörper gegen protein c
ATE86488T1 (de) Verwendung von minoxidil zur wundheilung.
DE3887750D1 (de) Selektive entfernung von immunkomplexen.
Waller et al. Immunochemical and serological studies of enzymatically fragmented human IgG globulins—II: Hydrolysis with subtilisin, elastase, trypsin, and chymotrypsin
DE58906338D1 (de) Kombination von Angiotensin-Converting-Enzyme-Hemmern mit Kaliumkanal-Modulatoren sowie deren Verwendung in Arzneimitteln.
Wier et al. Aproliferin--a human plasma protein that induces the irreversible loss of proliferative potential associated with terminal differentiation.
Stolinsky et al. ON THE UNIVALENT FRAGMENTS OF HUMAN 7 S GAMMA-GLOBULIN.
Abraham Human triclonal anti-IgG gammopathy. I. Iso-electric focusing characteristics of the IgG, IgA and IgM anti-IgG and their heavy and light chains.